Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.53 |
| ▸ | PPARA | Q07869 | 8/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750437 | 0.88 | PPARG (0.51) | PPARGPPARAMEN1KMT2ACNR2 | |
| SCHEMBL5749823 | 0.88 | MEN1 (0.48) | PPARGPPARAMAPK14MEN1KMT2A | |
| SCHEMBL5750403 | 0.86 | LDHA (0.51) | PPARGPPARAFFAR1 | |
| SCHEMBL5749813 | 0.86 | PPARA (0.50) | PPARGPPARALTA4HEPHX2FFAR1 | |
| SCHEMBL5751624 | 0.83 | PPARG (0.44) | PPARGPPARAKMT2AEPHX2CNR2 | |
| SCHEMBL5749682 | 0.83 | PPARG (0.44) | PPARGPPARAKMT2AEPHX2CNR2 | |
| SCHEMBL5754276 | 0.82 | MAPK14 (0.49) | PPARGPPARAMAPK14MEN1KMT2A | |
| SCHEMBL5753842 | 0.82 | PPARG (0.57) | PPARGPPARAFFAR1CNR2SRD5A2 | |
| SCHEMBL5750572 | 0.81 | PPARA (0.43) | PPARGPPARAEPHX2FFAR1SRD5A2 | |
| SCHEMBL5752446 | 0.78 | CETP (0.50) | PPARGPPARAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PPARG 905/4885PPARA 708/4885MAPK14 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.